Russia includes Elpida in its essential drugs list for HIV-1

6 September 2018

The Commission of the Russian Ministry of Health has included Elpida (elsulfavirine), US privately-held biotech firm Viriom's once-daily 20mg oral formulation of its innovative drug elsulfavirine, in Russia's List of Vital and Essential Drugs (VED).

Inclusion of Elpida, Viriom's best in class non-nucleoside reverse transcriptase inhibitor (NNRTI), provides full access to the drug for all patients and physicians for HIV treatment and prophylaxis, and is chiefly funded under the Russian government's State Strategy and Implementation Plan on HIV until 2020 and beyond.

Viriom obtained its first Russian marketing approval for Elpida in June 2017 for treatment of HIV-1 in combination with other antiretroviral medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK